絞り込み

16533

広告

Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms: Results From a Randomized Controlled Trial.

著者 Keefe RSE , Harvey PD , Khan A , Saoud JB , Staner C , Davidson M , Luthringer R
J Clin Psychiatry.2018 May 15 ; 79(3):.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (20view , 0users)

Full Text Sources

Current dopamine-blocking antipsychotic drugs have little impact on the cognitive deficits associated with schizophrenia. We evaluated whether MIN-101, a molecule that combines sigma-2 antagonism and 5-HT2A antagonism, might improve cognitive deficits in individuals with moderate to severe negative symptoms in schizophrenia.
PMID: 29873956 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード